Intensity modulated radiotherapy for localized prostate cancer: rigid compliance to dose-volume constraints as a warranty of acceptable toxicity?
© Chen et al; licensee BioMed Central Ltd. 2007
Received: 14 October 2006
Accepted: 15 January 2007
Published: 15 January 2007
To report the toxicity after intensity modulated radiotherapy (IMRT) for patients with localized prostate cancer, as a sole treatment or after radical prostatectomy.
Between August 2001 and December 2003, 132 patients with prostate cancer were treated with IMRT and 125 were evaluable to acute and late toxicity analysis, after a minimum follow-up time of one year. Clinical and treatment data, including normal tissue dose-volume histogram (DVH) constraints, were reviewed. Gastro-intestinal (GI) and genito-urinary (GU) signs and symptoms were evaluated according to the Radiation Therapy Oncology Group (RTOG) toxicity scales. Median prescribed dose was 76 Gy. Median follow-up time was of 26.1 months.
From the 125 patients, 73 (58.4%) presented acute Grade 1 or Grade 2 GI and 97 (77.2%) presented acute Grade 1 or Grade 2 GU toxicity. Grade 3 GI acute toxicity occurred in only 2 patients (1.6%) and Grade 3 GU acute toxicity in only 3 patients (2.4%). Regarding Grade 1 and 2 late toxicity, 26 patients (20.8%) and 21 patients (16.8%) presented GI and GU toxicity, respectively. Grade 2 GI late toxicity occurred in 6 patients (4.8%) and Grade 2 GU late toxicity in 4 patients (3.2%). None patient presented any Grade 3 or higher late toxicity. Non-conformity to DVH constraints occurred in only 11.2% of treatment plans. On univariate analysis, no significant risk factor was identified for Grade 2 GI late toxicity, but mean dose delivered to the PTV was associated to higher Grade 2 GU late toxicity (p = 0.042).
IMRT is a well tolerable technique for routine treatment of localized prostate cancer, with short and medium-term acceptable toxicity profiles. According to the data presented here, rigid compliance to DHV constraints might prevent higher incidences of normal tissue complication.
External-beam radiotherapy is the most utilized radiotherapy modality for treatment of localized prostate cancer and local control is related to delivered dose [1–4]. Three-dimensional conformal radiotherapy [3D-CRT) is a technique used to achieve this "dose escalation", but is limited by the consequent risk of excessive rectal and bladder complications [5, 6].
Recently, the development of the intensity modulated radiotherapy (IMRT) has been shown to be a reasonable option to deliver higher radiation doses to prostate cancer patients, with acceptable low rates of complications [7–9].
This study presents a retrospective evaluation of the initial toxicity following the technical implementation of IMRT, for treatment of localized prostate cancer patients. Clinical and treatment related factors, including normal tissue dose-volume histogram (DVH) constraints, were analyzed as possible risk factors for gastro-intestinal (GI) or genito-urinary (GU) toxicity.
Selection of patients
> 65 e ≤ 75
Highest serum PSA level (ng/ml):
> 10 e < 20
Stage (AJCC 1997):
T2aN0M0 or lower
T2bN0M0 or higher
8 – 10
Exclusive radiotherapy treatment
Neo-adjuvant hormonal therapy
Prognostic groups stratification and radiation doses prescriptions:
Highest serum PSA level (ng/ml)
> 10 e < 20
Stage (AJCC 1997)
≤ 6 (3 + 3)
OR 2 Intermediate Risk factors associated
Neo-adjuvant hormonal therapy
There was no restriction concerning hormone therapy and the usage was determined by physician's discretion, as an adjunct treatment to reduce prostatic volume or to "high risk" patients.
At the moment of the IMRT technique implantation, a class solution was established to be applied to all treatment plans. Before effective IMRT delivery, all patients were submitted to a pelvic CT simulation (CT-Sim) procedure. Using the CT-Sim data, and for planning calculation, the following structures were contoured: femoral heads, prostate and seminal vesicles, bladder and rectum (entirely contoured from the anal canal to rectum-sigmoid transition). The clinical target volume (CTV) corresponded to prostate and the entire seminal vesicles. For operated patients, (i.e.: after radical prostatectomy), the CTV corresponded to the prostatic and seminal vesicles bed, according to pre-operative CT or MRI scans. Margins of 0.6 cm (posterior) and 1.0 cm (cranial, caudal, anterior and laterals) were applied to the CTV when defining the planning target volume (PTV).
Dose-volume histogram and treatment volumes constraints:
Maximum Volume/Maximum Total Dose
≤ 55%/≥ 47 Gy
≤ 30%/≥ 70 Gy
Maximum dose: 82 Gy
≤ 55%/≥ 47 Gy
≤ 40%/≥ 65 Gy
≤ 25%/≥ 70 Gy
≤ 10%/≥ 75 Gy
Maximum dose: 82 Gy
Maximum dose: 50 Gy
Maximum dose ≤ 20% of prescription dose to PTV
Minimum dose of 70 Gy if prescription dose of 72 Gy to PTV
Minimum dose of 72 Gy if prescription dose of 74 Gy to PTV
Minimum dose of 74 Gy if prescription dose of 76 Gy to PTV
Minimum dose of 76 Gy if prescription dose of 78 Gy to PTV
PTV's coverage to a minimum of 95% of the entire volume
Immobilization and target localization's verification were regularly done utilizing a customized anatomical pelvic mold and weekly isocenter's anterior-posterior and laterals radiographs. Furthermore, all patients were ordered to evacuate before and keep the bladder full during the CT-Sim and all the daily applications, according to a proper routine. Treatment started effectively only after plan approval by both the radiation oncologist and the medical physicist and after "quality assurance" testing, also according to a proper routine.
All IMRT treatments were delivered successfully and median follow-up time was 26.1 months (range: 12.1 to 42.2 months). The median prescribed dose was 76 Gy, (range: 68 to 78 Gy), and the mean administered dose was 76.5 Gy, with median maximum and minimum doses of 81.8 Gy and 72 Gy, respectively.
Toxicity evaluation and follow-up
Data collection was done by retrospective review of medical files. Also, for each patient, a GI and GU toxicity assessment profile was created by the time of the IMRT treatment. Data obtained included relevant previous medical history (i.e.: diabetes, hypertension, previous surgery and ano-rectal or urinary diseases), medications and GI and GU symptoms. During treatment, all patients were evaluated on a weekly basis, regarding any new or worsening symptoms. Afterwards, patients were suggested to return to consultation with the radiation oncologist regularly, for clinical and digital rectal evaluation, which also included appraisal of GI and GU symptoms and serum PSA levels.
Acute toxicity was defined as the appearance or worsening of any GI or GU symptoms during treatment time or until after 6 months of it. Late toxicity was defined the same way, but after the 6th month of follow-up time. Either acute or late toxicity grading was scored based on the respective toxicity scales proposed by the Radiation Therapy Oncology Group (RTOG) [14–16].
Univariate exact logistic regression  was applied to test the association between any potential predictor and RTOG Grade 2 toxicity or higher. All significance probabilities (p values) presented are two-sided and values lower than 0,05 were considered statistically significant. "Odds ratios" and their respective 95% confidence intervals were estimated. The Logxact 6.3® software (Cytel Software Corporation, Cambridge, MA, USA) was utilized in all the statistical analysis.
Acute and late gastro-intestinal (GI) and genito-urinary (GU) toxicities profiles:
3 (2.4 %)
Compliance to DVH constraints as to different prescription dose:
Prescription doses levels
D74 (n = 44 patients)
D76 (n = 40 patients)
D78 (n = 41 patients)
Univariate analysis of prognostic factors to grade 2 or higher acute and late gastro-intestinal (GI) and genito-urinary (GU) toxicities:
Surgical status: operated
Neo-adjuvant hormonal therapy
Systemic Arterial Hypertension
No significant risk factor for GI Grade 2 or higher late toxicity was observed. Mean PTV doses correlated to GU Grade 2 or higher late toxicity as a significant risk factor (p = 0.042).
Results of local control, disease-free survival, PSA relapse-free survival or even global survival were not assessed, at the present study.
IMRT raised to radiation oncologists a possibility of tumour dose escalation without compromising doses to normal tissues. Since an initial publication by Zelefsky et al. , clinical utilization of this technique has been demonstrated to be safe, with acute and late rectal and bladder complications incidences at "acceptable" levels [8, 18–21]. This report adds some information about routine usage of dynamic IMRT technique, describing treatment complication frequencies, in a small, but consecutive sample of localized prostate cancer patients. Results of late GI and GU toxicities of about 15% (Grade 1) and lower than 5% (Grade 2) published here are very comparable to what has already been shown elsewhere [19, 21], as well as the elevated frequency of acute GI and GU toxicities, beyond 50%, but with rare cases of more severe complications [18–20].
Although results might seem to be very similar, proposed criteria to toxicity evaluation are very heterogeneous among the different already published reports. This analysis, however, was conceived taking advantage of widely used and very simple tools, which are the RTOG toxicities scales, in order to make data here easily understandable. An example is the report from Zelefsky et al. in which a higher importance was given to rectal bleeding as a sign of increased toxicity. Some of the bleeding complications were scored as Grade 3, (0.5% versus 1.5% for Grade 2 symptoms frequency), due to necessity of transfusion or laser cauterization procedures . In the data demonstrated here, however, of the total number of six patients (4.8%) who presented GI Grade 2 late toxicity, only three of them (2.4%) presented rectal bleeding which necessitated laser cauterization procedures and all of them remitted after treatment, neither evolving to obstruction nor to bleeding requiring surgery (data not shown).
On univariate analysis it was not observed any significant association between clinical factors or DVH constraints and risk of GI late toxicity, which could predict a Grade 2 or higher index, as is usually described [5–7, 22–24]. Frequency of complications was certainly low enough and there is no point to draw any precipitated conclusions about predisposing factors to rectal and bladder toxicity. A criticism to the data presented here could obviously be the negative influence of a heterogeneous group and of different treatment doses. These facts has certainly underpowered the analysis, leading to the absence of more instigating results.
Nonetheless, it must be stressed the lack of any Grade 3 late toxicity during the follow-up time, and an important reason might have been the rigid compliance to DVH constraints. Although the limit of acceptance for compliance to the DHV constraint levels was a random value of 3%, there was, as previously shown, a low rate of non-conformity to the them and, for the 14 patients with some degree of non-conformity, the "violation severity" was also of less than 6.5% (mean value, range: 3% – 21.3%).
As described earlier, the constraints utilized in the present study were elaborated based on data previously published in the literature. At the present moment, there is no ideal "set" of DVH constraints to be safely used, although there are some of these parameters that seem to be very strong predictors of GI and GU toxicity . In this sample, the "set" of DVH constraints presented seemed to be reliable, as the preliminary toxicity results were very acceptable.
Intensity modulated radiotherapy is a tolerable treatment technique for localized prostate cancer. Care must be taken, however, when applying literature data to daily practice, especially concerning dose escalation and the ensuing risks of normal tissue complications. A rigid compliance to dose-volume constraints derived from previously published experiences must always be observed as an additional tool to reduce treatment related risks and might be warranty of acceptable toxicity.
The authors are in debt with Lourenço Caprioglio and Roberto K. Sakuraba, for their invaluable contributions to this project.
- Hanks GE, Martz KL, Diamond JJ: The effect of dose on local control of prostate cancer. Int J Radiat Oncol Biol Phys 1988,15(6):1299-305.View ArticlePubMedGoogle Scholar
- Zelefsky MJ, Leibel SA, Gaudin PB, Kutcher GJ, Fleshner NE, Venkatramen ES, Reuter VE, Fair WR, Ling CC, Fuks Z: Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41(3):491-500. 1998 Jun 1 10.1016/S0360-3016(98)00091-1
- Hanks GE, Hanlon AL, Schultheiss TE, Pinover WH, Movsas B, Epstein BE, Hunt MA: Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 41(3):501-10. 1998 Jun 1 10.1016/S0360-3016(98)00089-3
- Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I: Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53(5):1097-105. 2002 Aug 1 10.1016/S0360-3016(02)02829-8
- Pollack A, Zagars GK, Starkschall G, Childress CH, Kopplin S, Boyer AL, Rosen II: Conventional vs. conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity. Int J Radiat Oncol Biol Phys 34(3):555-64. 1996 Feb 1 10.1016/0360-3016(95)02103-5
- Boersma LJ, van den Brink M, Bruce AM, Shouman T, Gras L, te Velde A, Lebesque JV: Estimation of the incidence of late bladder and rectum complications after high-dose (70–78 Gy) conformal radiotherapy for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys 41(1):83-92. 1998 Apr 1 10.1016/S0360-3016(98)00037-6
- Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, Reuter VE, Venkatraman ES, Leibel SA: High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001,166(3):876-81. 10.1016/S0022-5347(05)65855-7View ArticlePubMedGoogle Scholar
- Shu HK, Lee TT, Vigneauly E, Xia P, Pickett B, Phillips TL, Roach M: Toxicity following high-dose three-dimensional conformal and intensity-modulated radiation therapy for clinically localized prostate cancer. Urology 2001,57(1):102-7. 10.1016/S0090-4295(00)00890-6View ArticlePubMedGoogle Scholar
- Zelefsky MJ, Fuks Z, Happersett L, Lee HJ, Ling CC, Burman CM, Hunt M, Wolfe T, Venkatraman ES, Jackson A, Skwarchuk M, Leibel SA: Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 2000,55(3):241-9. 10.1016/S0167-8140(99)00100-0View ArticlePubMedGoogle Scholar
- Gleason DF: Histologic grading and clinical staging of prostate carcinoma. In Urologic pathology: the prostate. Edited by: Tannenbaum M. Philadelphia: Lea & Febiger; 1977:171-97.Google Scholar
- American Joint Comission on Staging of Cancer: Manual for staging of cancer. 5th edition. Philadelphia: JB Lippincott; 1997.Google Scholar
- Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Ku-ten A, Sternberg C, Gil T, Collette L, Pierart M: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337(5):295-300. 1997 Jul 31 10.1056/NEJM199707313370502
- Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, Wesson M: Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21(1):109-22. 1991 May 15
- Cox JD, Stetz J, Pajak TF: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31(5):1341-6. 1995 Mar 30 10.1016/0360-3016(95)00060-C
- Acute Radiation Morbidity Scoring Criteria[http://www.rtog.org/members/toxicity/acute.html]
- RTOG/EORTC Late Radiation Morbidity Scoring Schema[http://www.rtog.org/members/toxicity/late.html]
- Mehta CR, Patel NR: Exact logistic regression: theory and examples. Stat Med 14(19):2143-60. 1995 Oct 15
- Teh BS, Mai WY, Augspurger ME, Uhl BM, McGary J, Dong L, Grant WH 3rd, Lu HH, Woo SY, Carpenter LS, Chiu JK, Butler EB: Intensity modulated radiation therapy (IMRT) following prostatectomy: more favorable acute genitourinary toxicity profile compared to primary IMRT for prostate cancer. Int J Radiat Oncol Biol Phys 49(2):465-72. 2001 Feb 1 10.1016/S0360-3016(00)01474-7
- Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, Amols H, Venkatraman ES, Leibel SA: High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53(5):1111-6. 2002 Aug 1 10.1016/S0360-3016(02)02857-2
- De Meerleer G, Vakaet L, Meersschout S, Villeirs G, Verbaeys A, Oosterlinck W, De Neve W: Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients. Int J Radiat Oncol Biol Phys 60(3):777-87. 2004 Nov 1 10.1016/j.ijrobp.2004.04.017
- Brabbins D, Martinez A, Yan D, Lockman D, Wallace M, Gustafson G, Chen P, Vicini F, Wong J: A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity. Int J Radiat Oncol Biol Phys 61(2):400-8. 2005 Feb 1 10.1016/j.ijrobp.2004.06.001
- Pollack A, Hanlon A, Horwitz EM, Feigenberg S, Uzzo RG, Price RA: Radiation therapy dose escalation for prostate cancer: a rationale for IMRT. World J Urol 2003,21(4):200-8. 10.1007/s00345-003-0356-xView ArticlePubMedGoogle Scholar
- Fiorino C, Cozzarini C, Vavassori V, Sanguineti G, Bianchi C, Cattaneo GM, Foppiano F, Magli A, Piazzolla A: Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: analysis of a large group of patients pooled from three institutions. Radiother Oncol 2002,64(1):1-12. 10.1016/S0167-8140(02)00147-0View ArticlePubMedGoogle Scholar
- Herold DM, Hanlon AL, Hanks GE: Diabetes mellitus: a predictor for late radiation morbidity. Int J Radiat Oncol Biol Phys 43(3):475-9. 1999 Feb 1 10.1016/S0360-3016(98)00460-X
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.